The Silence of the Bioethicists
By Leigh Turner,
Impact Ethics
| 03. 24. 2014
Last week, Kirstin Borgerson, a philosopher at Dalhousie University, published a
thoughtful commentary on my colleague Carl Elliott’s
persistent call for an investigation of Dan Markingson’s death and psychiatric research misconduct at the University of Minnesota. Dan Markingson was a young man from St. Paul who
committed suicide by nearly decapitating himself while enrolled in a psychiatric drug study at the University of Minnesota Medical Center, Fairview.In analyzing the audience’s response to Carl’s public lecture, alongside the typical response of her undergraduate students, Borgerson notes that there was no animated discussion of ethical issues in the Markingson case because “very simply, there is nothing to debate.” Borgerson adds,
Among serious scholars, there is no defense of the practice of: radically violating informed consent …; enrolling suicidal patients in the sort of risky trial that Markingson was enrolled in; having researchers disrespect and disregard concerns raised by family members about the well-being of research subjects during a trial; or creating conditions under which researchers are motivated to enroll subjects so as not to lose out on tens of thousands of...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...